Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and enterococci by FIC index and timed-kill curves

被引:38
作者
Snydman, DR [1 ]
McDermott, LA [1 ]
Jacobus, NV [1 ]
机构
[1] Tufts Univ, New England Med Ctr, Boston, MA 02111 USA
关键词
checkerboard methods; time-kill curves; synergy; antagonism; bactericidal effect; daptomycin;
D O I
10.1179/joc.2005.17.6.614
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The interactions of daptomycin with gentamicin and 5 beta-lactam agents were determined by checkerboard and timed-kill studies. Eighty isolates were tested by checkerboard: 20 each of methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible Staphylococcus aureus (MSSA), vancomycin-susceptible Enterococcus faecalis (VSEF) and vancomycin-resistant enterococci (VRE). Time kill curves were performed on 8 selected isolates: 2 each of MRSA, MSSA, VSEF and VRE. Checkerboard results showed highest frequency of synergistic effects against VSEF (35-75%) with daptomycin combined with ceftriaxone, cefepime or imipenem; a modest effect with most combinations against VRE and MRSA (520%); and indifference with daptomycin and most agents against MSSA (0-5%); except with daptomycin with oxacillin where 10-20% synergy was observed. Synergistic interaction was confirmed by time kill studies in seven of ten isolates where checkerboard suggested synergy. A bactericidal effect was exerted in 5/7 synergistic combinations. The in vitro data suggest that daptomycin combined with other antibiotics may be microbiologically beneficial and not antagonistic.
引用
收藏
页码:614 / 621
页数:8
相关论文
共 18 条
[1]  
ATKINS RL, 2000, ANTIMICROB AGENTS CH, V44, P1925
[2]   In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers [J].
Barry, AL ;
Fuchs, PC ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1919-1922
[3]   BACTERICIDAL ACTIVITY OF VANCOMYCIN, DAPTOMYCIN, AMPICILLIN AND AMINOGLYCOSIDES AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM [J].
BINGEN, E ;
LAMBERTZECHOVSKY, N ;
LECLERCQ, R ;
DOIT, C ;
MARIANIKURKDJIAN, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (05) :619-626
[4]  
ELIPOLUS GM, 1996, ANTIBIOTICS LAB MED
[5]   Antimicrobial resistance in intensive care units [J].
Fridkin, SK ;
Gaynes, RP .
CLINICS IN CHEST MEDICINE, 1999, 20 (02) :303-+
[6]   ANTIMICROBIAL ACTIVITY AND SPECTRUM OF LY146032, A LIPOPEPTIDE ANTIBIOTIC, INCLUDING SUSCEPTIBILITY TESTING RECOMMENDATIONS [J].
JONES, RN ;
BARRY, AL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (04) :625-629
[7]   The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates [J].
King, A ;
Phillips, I .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (02) :219-223
[8]   EFFECTS OF COMBINATIONS OF BETA-LACTAMS, DAPTOMYCIN, GENTAMICIN, AND GLYCOPEPTIDES AGAINST GLYCOPEPTIDE-RESISTANT ENTEROCOCCI [J].
LECLERCQ, R ;
BINGEN, E ;
SU, QH ;
LAMBERTZECHOVSKI, N ;
COURVALIN, P ;
DUVAL, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (01) :92-98
[9]   COMPARISON OF IN-VITRO INHIBITORY AND BACTERICIDAL ACTIVITIES OF DAPTOMYCIN (LY-146032) AND 4 REFERENCE ANTIBIOTICS, SINGLY AND IN COMBINATION, AGAINST GENTAMICIN-SUSCEPTIBLE AND HIGH-LEVEL-GENTAMICIN-RESISTANT ENTEROCOCCI [J].
LOUIE, A ;
BALTCH, AL ;
RITZ, WJ ;
SMITH, RP ;
ASPERILLA, M .
CHEMOTHERAPY, 1993, 39 (05) :302-310
[10]  
*NCCLS, 1992, M26T NCCLS, V12